ResMed (NYSE:RMD – Get Free Report) announced its earnings results on Thursday. The medical equipment provider reported $2.08 EPS for the quarter, topping the consensus estimate of $2.03 by $0.05, Briefing.com reports. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.22 billion. ResMed had a return on equity of 25.58% and a net margin of 21.79%. ResMed’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.60 EPS.
ResMed Trading Up 4.2 %
Shares of ResMed stock traded up $9.08 on Friday, hitting $223.64. 2,659,791 shares of the company’s stock traded hands, compared to its average volume of 925,655. The firm’s 50-day moving average price is $203.89 and its two-hundred day moving average price is $196.47. The stock has a market capitalization of $32.85 billion, a PE ratio of 34.35, a price-to-earnings-growth ratio of 1.85 and a beta of 0.66. ResMed has a one year low of $132.24 and a one year high of $225.68. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.04 and a quick ratio of 1.97.
ResMed Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.53 per share. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date is Thursday, August 15th. This represents a $2.12 annualized dividend and a dividend yield of 0.95%. ResMed’s payout ratio is presently 29.49%.
Insider Buying and Selling at ResMed
Wall Street Analyst Weigh In
Several brokerages have recently commented on RMD. Oppenheimer downgraded ResMed from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 25th. Royal Bank of Canada boosted their price objective on shares of ResMed from $204.00 to $206.00 and gave the stock a “sector perform” rating in a research report on Friday. Citigroup cut shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Monday, June 24th. Needham & Company LLC restated a “buy” rating and issued a $236.00 price objective on shares of ResMed in a research report on Friday. Finally, KeyCorp boosted their price objective on shares of ResMed from $238.00 to $251.00 and gave the stock an “overweight” rating in a research report on Friday. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, ResMed has an average rating of “Moderate Buy” and a consensus price target of $204.70.
About ResMed
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Recommended Stories
- Five stocks we like better than ResMed
- How to Use the MarketBeat Stock Screener
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- How to Invest in Insurance Companies: A GuideĀ
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Technology Stocks Explained: Here’s What to Know About Tech
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.